{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:38:28Z","timestamp":1783633108694,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-022-03160-2","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T02:05:21Z","timestamp":1665108321000},"page":"380-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bone metastases in midgut neuroendocrine tumors: imaging characteristics, distribution, and risk factors"],"prefix":"10.1007","volume":"78","author":[{"given":"Maxime","family":"Leli\u00e8vre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Katherine Anna","family":"Triumbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedia","family":"Brixi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cadiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Deguelte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-4841","authenticated-orcid":false,"given":"David","family":"Morland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"3160_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"J. Hallet, C.H.L. Law, M. Cukier, R. Saskin, N. Liu, S. Singh, Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121, 589\u2013597 (2015). https:\/\/doi.org\/10.1002\/cncr.29099","journal-title":"Cancer"},{"key":"3160_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"A. Dasari, C. Shen, D. Halperin, B. Zhao, S. Zhou, Y. Xu, T. Shih, J.C. Yao, Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335\u20131342 (2017). https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589","journal-title":"JAMA Oncol."},{"key":"3160_CR3","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3390\/cancers11091332","volume":"11","author":"B Altieri","year":"2019","unstructured":"B. Altieri, C. Di Dato, C. Martini, C. Sciammarella, A. Di Sarno, A. Colao, A. Faggiano, Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management. Cancers 11, 1332 (2019). https:\/\/doi.org\/10.3390\/cancers11091332","journal-title":"Cancers"},{"key":"3160_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000335597","volume":"95","author":"M Pavel","year":"2012","unstructured":"M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. \u00d6berg, T. Steinm\u00fcller, M. Anlauf, B. Wiedenmann, R. Salazar; Barcelona Consensus Conference participants, ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95, 157\u2013176 (2012). https:\/\/doi.org\/10.1159\/000335597","journal-title":"Neuroendocrinology"},{"key":"3160_CR5","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1007\/s00330-020-07554-6","volume":"31","author":"N Deleval","year":"2021","unstructured":"N. Deleval, L. Pesque, A. Dieudonn\u00e9, F. Viry, O. Hentic, R. Lebtahi, P. Ruszniewski, L. de Mestier, Prognostic impact of bone metastases detected by 18F-DOPA PET in patients with metastatic midgut neuroendocrine tumors. Eur. Radiol. 31, 4166\u20134174 (2021). https:\/\/doi.org\/10.1007\/s00330-020-07554-6","journal-title":"Eur. Radiol."},{"key":"3160_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000457954","volume":"106","author":"M Scharf","year":"2018","unstructured":"M. Scharf, V. Petry, H. Daniel, A. Rinke, T.M. Gress, Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance. Neuroendocrinology 106, 30\u201337 (2018). https:\/\/doi.org\/10.1159\/000457954","journal-title":"Neuroendocrinology"},{"key":"3160_CR7","first-page":"184","volume":"44","author":"WG Meijer","year":"2003","unstructured":"W.G. Meijer, E. Veer, P.L. van der; Jager, E.J. Jagt, B.A. van der; Piers, I.P. Kema, E.G.Ede Vries, P.H.B. Willemse, Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J. Nucl. Med. 44, 184\u2013191 (2003)","journal-title":"J. Nucl. Med."},{"key":"3160_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/EC-14-0119","volume":"4","author":"K Van Loon","year":"2015","unstructured":"K. Van Loon, L. Zhang, J. Keiser, C. Carrasco, K. Glass, M.-T. Ramirez, S. Bobiak, E.K. Nakakura, A.P. Venook, M.H. Shah et al. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr. Connect. 4, 9\u201317 (2015). https:\/\/doi.org\/10.1530\/EC-14-0119","journal-title":"Endocr. Connect."},{"key":"3160_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0002-9343(85)90313-4","volume":"79","author":"EM Ross","year":"1985","unstructured":"E.M. Ross, W.C. Roberts, The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am. J. Med. 79, 339\u2013354 (1985). https:\/\/doi.org\/10.1016\/0002-9343(85)90313-4","journal-title":"Am. J. Med."},{"key":"3160_CR10","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"M.F. Bozkurt, I. Virgolini, S. Balogova, M. Beheshti, D. Rubello, C. Decristoforo, V. Ambrosini, A. Kjaer, R. Delgado-Bolton, J. Kunikowska et al. Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging 44, 1588\u20131601 (2017). https:\/\/doi.org\/10.1007\/s00259-017-3728-y","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"3160_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.dld.2020.02.011","volume":"52","author":"L de Mestier","year":"2020","unstructured":"L. de Mestier, C. Lepage, E. Baudin, R. Coriat, F. Courbon, A. Couvelard, C. Do Cao, E. Frampas, S. Gaujoux, R. Gincul et al. Digestive neuroendocrine neoplasms (NEN): French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig. Liver Dis. 52, 473\u2013492 (2020). https:\/\/doi.org\/10.1016\/j.dld.2020.02.011","journal-title":"Dig. Liver Dis."},{"key":"3160_CR12","first-page":"1455","volume":"47","author":"F Montravers","year":"2006","unstructured":"F. Montravers, D. Grahek, K. Kerrou, P. Ruszniewski, V. de Beco, N. Aide, F. Gutman, J.-D. Grang\u00e9, J.-P. Lotz, J.-N. Talbot, Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J. Nucl. Med. 47, 1455\u20131462 (2006)","journal-title":"J. Nucl. Med."},{"key":"3160_CR13","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1200\/JCO.2007.15.1126","volume":"26","author":"KP Koopmans","year":"2008","unstructured":"K.P. Koopmans, O.C. Neels, I.P. Kema, P.H. Elsinga, W.J. Sluiter, K. Vanghillewe, A.H. Brouwers, P.L. Jager, E.G.E. de Vries, Improved staging of patients with carcinoid and islet cell tumors with 18F-Dihydroxy-Phenyl-Alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 26, 1489\u20131495 (2008). https:\/\/doi.org\/10.1200\/JCO.2007.15.1126","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"3160_CR14","first-page":"1161","volume":"45","author":"A Becherer","year":"2004","unstructured":"A. Becherer, M. Szab\u00f3, G. Karanikas, P. Wunderbaldinger, P. Angelberger, M. Raderer, A. Kurtaran, R. Dudczak, K. Kletter, Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J. Nucl. Med. Publ. Soc. Nucl. Med. 45, 1161\u20131167 (2004)","journal-title":"J. Nucl. Med. Publ. Soc. Nucl. Med."},{"key":"3160_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1210\/jc.2008-1349","volume":"94","author":"F Montravers","year":"2009","unstructured":"F. Montravers, K. Kerrou, V. Nataf, V. Huchet, J.-P. Lotz, P. Ruszniewski, P. Rougier, F. Duron, P. Bouchard, J.-D. Grang\u00e9 et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J. Clin. Endocrinol. Metab. 94, 1295\u20131301 (2009). https:\/\/doi.org\/10.1210\/jc.2008-1349","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3160_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/RLU.0000000000003450","volume":"46","author":"C Ansquer","year":"2021","unstructured":"C. Ansquer, Y. Touchefeu, A. Faivre-Chauvet, C. Leux, M. Le Bras, N. R\u00e9genet, V. Fleury, B. Maucherat, H. Senellart, S. Guyetant et al. Head-to-head comparison of 18F-DOPA PET\/CT and 68Ga-DOTANOC PET\/CT in patients with midgut neuroendocrine tumors. Clin. Nucl. Med. 46, 181\u2013186 (2021). https:\/\/doi.org\/10.1097\/RLU.0000000000003450","journal-title":"Clin. Nucl. Med."},{"key":"3160_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/cen.14527","volume":"95","author":"A Piccardo","year":"2021","unstructured":"A. Piccardo, F. Fiz, G. Bottoni, M. Ugolini, W. Noordzij, P. Trimboli, Head-to-head comparison between 18 F-DOPA PET\/CT and 68 Ga-DOTA peptides PET\/CT in detecting intestinal neuroendocrine tumours: a systematic review and meta-analysis. Clin. Endocrinol. 95, 595\u2013605 (2021). https:\/\/doi.org\/10.1111\/cen.14527","journal-title":"Clin. Endocrinol."},{"key":"3160_CR18","doi-asserted-by":"publisher","unstructured":"E. Ouvrard, L.D. Mestier, C. Boursier, B. Lachachi, N. Sahakian, E. Chevalier, N. Mikail, J. Carullo, A. Bando-Delaunay, T. Walter et al. 18F-Fluorodihydroxyphenylalanine PET\/CT at the forefront for initial and\/or pre-surgical evaluation of small intestine neuroendocrine tumors. J. Nucl. Med. (2022). https:\/\/doi.org\/10.2967\/jnumed.122.263984","DOI":"10.2967\/jnumed.122.263984"},{"key":"3160_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/RLU.0000000000004057","volume":"47","author":"D Morland","year":"2022","unstructured":"D. Morland, P. Jallerat, H. Brixi, G. Cadiot, D. Papathanassiou, S. Deguelte, Performances of 18F-FDOPA PET\/CT in the preoperative evaluation of the peritoneal cancer index in small intestine neuroendocrine tumors. Clin. Nucl. Med. 47, 294\u2013298 (2022). https:\/\/doi.org\/10.1097\/RLU.0000000000004057","journal-title":"Clin. Nucl. Med."},{"key":"3160_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"I.D. Nagtegaal, R.D. Odze, D. Klimstra, V. Paradis, M. Rugge, P. Schirmacher, K.M. Washington, F. Carneiro, I.A. Cree; WHO Classification of Tumours Editorial Board, The 2019 WHO classification of tumours of the digestive system. Histopathology 76, 182\u2013188 (2020). https:\/\/doi.org\/10.1111\/his.13975","journal-title":"Histopathology"},{"key":"3160_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000287255","volume":"91","author":"B Kos-Kud\u0142a","year":"2010","unstructured":"B. Kos-Kud\u0142a, D. O\u2019Toole, M. Falconi, D. Gross, G. Kl\u00f6ppel, A. Sundin, J. Ramage, K. Oberg, B. Wiedenmann, P. Komminoth et al. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 91, 341\u2013350 (2010). https:\/\/doi.org\/10.1159\/000287255","journal-title":"Neuroendocrinology"},{"key":"3160_CR22","doi-asserted-by":"publisher","first-page":"102168","DOI":"10.1016\/j.ctrv.2021.102168","volume":"94","author":"E Garcia-Torralba","year":"2021","unstructured":"E. Garcia-Torralba, F. Spada, K.H.J. Lim, T. Jacobs, J. Barriuso, W. Mansoor, M.G. McNamara, R.A. Hubner, P. Manoharan, N. Fazio et al. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: a systematic review and meta-analysis. Cancer Treat. Rev. 94, 102168 (2021). https:\/\/doi.org\/10.1016\/j.ctrv.2021.102168","journal-title":"Cancer Treat. Rev."},{"key":"3160_CR23","doi-asserted-by":"publisher","unstructured":"D. Morland, L. Jallet, S. Deguelte, G. Cadiot, D. Papathanassiou, Orbital metastasis: a rare but typical location of small intestine neuroendocrine tumor on 18F-FDOPA PET\/CT. Clin. Nucl. Med. (2022). https:\/\/doi.org\/10.1097\/RLU.0000000000004137","DOI":"10.1097\/RLU.0000000000004137"},{"key":"3160_CR24","unstructured":"E. Ziu, V.K. Viswanathan, F.B. Mesfin, Spinal metastasis, (StatPearls Publishing, 2021)"},{"key":"3160_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/MPA.0000000000000267","volume":"44","author":"J Kavecansky","year":"2015","unstructured":"J. Kavecansky, L. Wei, L. Caronia, M.-T. Ramirez, M. Bloomston, M.H. Shah, Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio State University Medical Center. Pancreas 44, 198\u2013203 (2015). https:\/\/doi.org\/10.1097\/MPA.0000000000000267","journal-title":"Pancreas"},{"key":"3160_CR26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/00006231-200208000-00006","volume":"23","author":"JM Zuetenhorst","year":"2002","unstructured":"J.M. Zuetenhorst, C.A. Hoefnageli, H. Boot, R.A. Vald\u00e9s Olmos, B.G. Taal, Evaluation of (111)In-Pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl. Med. Commun. 23, 735\u2013741 (2002). https:\/\/doi.org\/10.1097\/00006231-200208000-00006","journal-title":"Nucl. Med. Commun."},{"key":"3160_CR27","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/ijc.30400","volume":"139","author":"M Riihim\u00e4ki","year":"2016","unstructured":"M. Riihim\u00e4ki, A. Hemminki, K. Sundquist, J. Sundquist, K. Hemminki, The epidemiology of metastases in neuroendocrine tumors. Int. J. Cancer 139, 2679\u20132686 (2016). https:\/\/doi.org\/10.1002\/ijc.30400","journal-title":"Int. J. Cancer"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03160-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03160-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03160-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T19:31:21Z","timestamp":1666294281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03160-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["3160"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03160-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"27 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was conducted in accordance with the Declaration of Helsinki and was declared on the Health Data Hub (N\u00b0F20220506115447) in conformity with the reference methodology MR004 of the \u201cCommission Nationale de l\u2019Informatique et des Libert\u00e9s\u201d, allowing the computerized management of medical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The participants were informed of the possibility of using the information concerning them and had a right of opposition.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}